Cochrane · systematic review · CD009948
Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy‐naive advanced non‐small cell lung cancer
Yang, ZY, Liu, L, Mao, C, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
Lung CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 4 · 66.7%Moderate 0 · 0%High 2 · 33.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Comparison
Population: Patients with advanced non‐small cell lung cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival1 | HR 0.87 [0.79, 0.96] | 4 studies · 2018 participants | High |
Progression‐free survival1 | HR 0.91 [0.83, 1] | 4 studies · 2018 participants | Low Downgraded: risk of bias, imprecision |
One‐year survival rate2 | RR 1.13 [1.02, 1.25] | 4 studies · 2018 participants | High |
Objective response rate2 | RR 1.31 [1.14, 1.51] | 4 studies · 2018 participants | Low Downgraded: risk of bias, imprecision |
Quality of life3 | no estimate extracted | 2 studies · 1801 participants | Low Downgraded: risk of bias, imprecision |
Serious adverse events2,4 | RR 37.36 [10.66, 130.95] | 1 study · 4 participants | Low Downgraded: risk of bias, imprecision |